Open AccessAdverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study
Author(s) -
Ballari Brahmachari,
Avijit Hazra,
Anup Majumdar
Publication year - 2011
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.77341
Subject(s) - paclitaxel , observational study , drug , adverse effect , pharmacology , medicine , adverse drug reaction , chemotherapy
Conventional polyethoxylated castor oil (PCO)-based paclitaxel is associated with major adverse drug reactions (ADRs). Nanoxel, a nanoparticle-based formulation, may improve its tolerability by removing the need for PCO vehicle, and also permit its use in a higher dose. We conducted intensive monitoring of the ADR profile of Nanoxel in comparison with conventional paclitaxel in a public tertiary care set-up.